28th Jul 2016 09:05
LONDON (Alliance News) - Oxford BioMedica PLC on Thursday said it has received approvals from the UK Medicines & Healthcare products Regulatory Agency to manufacture bulk drug material for investigational medicinal products at its new facilities.
The gene and cell therapy group recently established and commissioned a second specialist bioprocessing clean room suite at Harrow House and at its new laboratories at Windrush Court for analytical testing. Both sites, in Oxford, are now completely developed and fully operational.
Oxford BioMedica will fully vacate its original Medawar Centre facility by the end of October.
"The new world-class facilities have been designed to be highly flexible so as to serve the group and its partners well for many years. We are now able to exploit our LentiVector platform to its full potential and we are excited by the progress we have made in developing a 200 litre serum-free suspension production process which allows significantly larger volumes of vector to be produced at significantly lower cost per patient dose," Chief Executive John Dawson said in a statement.
Shares in Oxford BioMedica were trading up 2.4% at 4.22 pence on Thursday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica